Each year in the United States, nearly two million people are diagnosed with cancer. Globally, it’s the second leading cause of death—and by 2040, annual cancer cases are projected to surge to nearly 30 million, with more than 15 million deaths. At BeOne Medicines, we’re addressing this staggering challenge head-on. We are committed to uniting the worldwide community against cancer by delivering innovative medicines faster and expanding access for patients, wherever they live.
A key pillar of our bold vision to eradicate cancer is firmly rooted in New Jersey. One year ago, we advanced that mission by opening our flagship U.S. biologics manufacturing and clinical R&D facility in Hopewell—a vital hub powering our efforts to build a next-generation oncology company driven by innovation, access, and speed.
A Bold Investment in Advancing Cancer Treatment in the U.S.
With an initial team gathering 15 years ago across the river in Valley Forge—and one of our first offices in Philadelphia—we understood this region’s prominent role in fighting cancer. With subsequent investments and collaborations—including with Merck, Janssen, Celgene, and BMS—our purpose and footprint have steadily grown. Today, that commitment continues, most notably through our $800 million investment at the Princeton West Innovation Campus in Hopewell. This 400,000-square-foot facility spans 42 acres and serves as a clinical and commercial-stage manufacturing hub for our oncology pipeline, supporting both small molecule and biologic therapies, including the future production of products like TEVIMBRA® (tislelizumab-jsgr).
It reflects our commitment to producing innovative medicines here in the U.S.—close to the patients and providers who need them—and expanding our domestic manufacturing capacity. It also enhances our global clinical and commercial capabilities, enabling us to produce at scale, ensure supply chain resilience, and position the U.S. at the leading edge of advancing cancer care.
Over the past year, the facility has created over 200 jobs across roles in science, technology, engineering, manufacturing, and beyond—strengthening both New Jersey’s and America’s life sciences innovation ecosystem.
Advancing Cancer Research & Impact Across America
With more than 1,800 colleagues across the U.S., our team plays a critical role in driving America’s leadership in cancer treatment innovation through investment, infrastructure, and partnerships. In 2024, we invested more than $750 million in U.S. R&D, powering bold science and accelerating progress for patients.
That commitment extends to the over 90 clinical trials we are conducting across nearly all 50 states in partnership with over 500 investigators. These trials are essential to bringing new treatments to cancer patients and fueling one of the largest and most compelling oncology pipelines in the industry.
With more than 45 molecules in clinical or commercial stages globally, and an R&D team of over 4,900, we’re focused on rapidly delivering innovation for some of the most challenging cancers, including blood, lung, breast, and gastrointestinal cancers.
But that scientific strength is only meaningful if it reaches the people who need it. At BeOne, broad patient access is engineered into our model—from trial design and site selection to manufacturing scale and delivery. Since our inception, we’ve focused on reducing barriers and embedding access into our processes so that more patients, regardless of geography, income, or background, can benefit from the therapies we’re working to bring forward.
Strengthening Cancer Care Through Community Partnership
This milestone also marks another year of deepening engagement within the cancer community. We believe patient organizations are vital partners in our collective mission to support those impacted by cancer—a commitment rooted in our core value of Patients First. That’s why we’ve built relationships with more than 60 patient groups and advocates across the U.S., collaborating to ensure patients and caregivers can access the information, support, and resources they need throughout their journey.
One partnership we’re especially proud of is with Crossroads4Hope, a nonprofit headquartered in New Jersey supporting people affected by cancer across the state and nationally. BeOne is supporting the expansion of their Health Champion Program, an important initiative that trains, activates, and mobilizes lay community members as trusted “first responders.” These champions are equipped to recognize and respond to the emotional, social, and practical needs of people facing cancer, connect them to care faster, and support more confident, shared decision-making.
Hopewell and Beyond: Scaling Innovation for Patients Everywhere
As we mark the one-year anniversary of our Hopewell facility, we’re reminded that meaningful progress happens when innovation, access, and urgency are scaled with purpose. Hopewell stands as a symbol of that ambition—a launchpad for accelerating science, expanding access, and reaching more patients, faster.
That approach has shaped everything we’ve built globally: our end-to-end R&D model, in-house manufacturing capabilities, internal clinical trials engine, and the partnerships and access strategies that have helped us reach more than 1.7 million patients worldwide.
Nearly 15 years into our journey, we remain committed to building a different kind of company: one that doesn’t just develop transformative treatments but ensures they’re within reach. We have accomplished much in our first 15 years, but our focus is now on the next 15—and fighting boldly to reduce the 15 million annual cancer deaths projected by 2040. The work ahead is ambitious, and we’re just getting started.
John V. Oyler is Co-Founder, Chairman, and Chief Executive Officer, and Matt Shaulis is General Manager, North America, at BeOne Medicines, a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.
